The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial

Objectives: The primary objective is to determine the efficacy of a single dose of ivermectin, administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptom onset to reduce the proportion of patients with detectable SARS-CoV-2 RNA by Polymerase Chain Reaction (PCR) test...

Descripción completa

Detalles Bibliográficos
Autores: Chaccour, Carlos, Ruiz Castillo, Paula, Richardson, Mary-Ann, Moncunill Piñas, Gemma, Casellas, Aina, Carmona Torre, Francisco, Giráldez, Miriam, Schwartz Mota, Juana, Yuste, José R., Azanza, José Ramón, Fernández, Miriam, Reina, Gabriel, Dobaño, Carlota, 1969-, Brew, Joe, Sadaba, Belen, Hammann, Felix, Rabinovich, Regina
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/174448
Acceso en línea:https://hdl.handle.net/2445/174448
Access Level:acceso abierto
Palabra clave:SARS-CoV-2
Medicaments antivírics
Antiviral agents
Descripción
Sumario:Objectives: The primary objective is to determine the efficacy of a single dose of ivermectin, administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptom onset to reduce the proportion of patients with detectable SARS-CoV-2 RNA by Polymerase Chain Reaction (PCR) test from nasopharyngeal swab at day 7 post-treatment.

Similares en LA Referencia